Program
neracorvir
Also written as “GST-HG141” and “GST-HG141 tablets”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fujian Akeylink Biotechnology | 43 open or running | phase 3since Jul 15, 2025 | Nov 24, 2022 | Dec 1, 2026phase 3 · NCT07090759 |
| Fujian Cosunter Pharmaceutical | 20 open or running | phase 1since May 7, 2020 | May 7, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2020First study: phase 1 study in Hepatitis BNew to Fujian Cosunter PharmaceuticalFujian Cosunter Pharmaceutical · NCT04386915 · 104 enrolled · China
- Apr 23, 2021Phase 1 study in Hepatitis BFujian Cosunter Pharmaceutical · NCT04868981 · 30 enrolled · China
- Nov 24, 2022Fujian Akeylink Biotechnology's first study: phase 2 study in Hepatitis B, ChronicNew to Fujian Akeylink BiotechnologyFujian Akeylink Biotechnology · NCT05637541 · 90 enrolled · China
- Jul 15, 2025Phase 3 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07090759 · 526 planned · China
- Apr 23, 2026Phase 3 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07588009 · 576 planned
- Jul 12, 2026Phase 2 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07709520 · 80 planned · China
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07090759
- Jan 11, 2028Primary completion: phase 3 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07588009
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07709520Hepatitis B, Chronic · China | 2 | Recruiting | Fujian Akeylink Biotechnology | Oct 1, 2026 | 80 |
| NCT07588009Hepatitis B, Chronic | 3 | Not yet recruiting | Fujian Akeylink Biotechnology | Jan 11, 2028 | 576 |
| NCT07090759Hepatitis B, Chronic · China | 3 | Recruiting | Fujian Akeylink Biotechnology | Dec 1, 2026 | 526 |
| NCT05637541Hepatitis B, Chronic · China | 2 | Completed | Fujian Akeylink Biotechnology | Jul 24, 2024 | 90 |
| NCT04868981Hepatitis B · China | 1 | Completed | Fujian Cosunter Pharmaceutical | Feb 23, 2022 | 30 |
| NCT04386915Hepatitis B · China | 1 | UNKNOWN | Fujian Cosunter Pharmaceutical | May 30, 2021 | 104 |
How it is read
Names in the registry
- “GST-HG141”, 4 entries
- “GST-HG141 tablets”, 2 entries
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 4 studies
- Hepatitis B, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.